JPMorgan analyst Eric Joseph added Revolution Medicines to the firm’s Analyst Focus List as a growth strategy and placed the shares on “Positive Catalyst Watch” for the Q4. The firm says Revolution has multiple RMC-6236 lung cancer readouts due in Q4. The analyst views an over 35% overall response rate with over eight months progression-free survival as the bar to secure the second-line opportunity for RMC-6236 monotherapy, and sees the stock trading to $50-$57 under “clean win” and “homerun” scenarios. JPMorgan keeps an Overweight rating on the name with a $54 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVMD:
- 3 Best Stocks to Buy Now, 9/18/2024, According to Top Analysts
- Revolution Medicines added to Analyst Current Favorites list at Raymond James
- Revolution Medicines Appoints Frank Clyburn to Expanded Board
- Revolution Medicines reiterates 2024 GAAP net loss guidance
- Revolution Medicines reports Q2 EPS (81c), consensus (77c)
Questions or Comments about the article? Write to editor@tipranks.com